Recent studies have exhibited the importance of the interactions of immune checkpoint inhibitory receptors with cognate ligands, such as program cell death protein 1 (PD-1) and PD-1Ls, and cytotoxic cell lymphocyte antigen-4 (CTLA-4) and CD80/CD86 interactions for cancer therapy [13,14,15]. The gene discussed is PDCD1; the disease is cancer.